OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
ERS Genomics and Japan SLC have signed a non-exclusive license agreement, allowing Japan SLC access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
ERS Genomics and Japan SLC, a biotechnology company that provides animal models to the research community, have signed a non-exclusive license agreement, allowing Japan SLC access to ERS Genomics’ clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 patent portfolio. According to a July 27, 2021 press release, through this access, Japan SLC will be able to expand its offering.
“We are proud to add Japan SLC to our growing list of partners in Japan applying CRISPR/Cas9 technology to its service offerings,” said Eric Rhodes, CEO of ERS Genomics, in the press release. “Japan SLC’s animal production and supply are of high quality, and we are very pleased that it has chosen to license CRISPR/Cas9 technology through ERS Genomics.”
“Our production and supply of laboratory animals will benefit greatly through the use of the revolutionary CRISPR/Cas9 technology,” added Hirotaka Takagi, president, Japan SLC, in the press release. “We are very excited to sign this licensing agreement with ERS Genomics which will enable us to produce CRISPR-edited mouse and rat models.”
The financial details of the non-exclusive agreement were not disclosed.
Source: ERS Genomics